- Home
- JKHY vs UTHR Comparison
JKHY vs UTHR Comparison
Compare JKHY & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- UTHR
- Stock Information
- Founded
- JKHY 1976
- UTHR 1996
- Country
- JKHY United States
- UTHR United States
- Employees
- JKHY N/A
- UTHR N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- JKHY Technology
- UTHR Health Care
- Exchange
- JKHY Nasdaq
- UTHR Nasdaq
- Market Cap
- JKHY 12.6B
- UTHR 20.7B
- IPO Year
- JKHY N/A
- UTHR 1999
- Fundamental
- Price
- JKHY $163.36
- UTHR $468.57
- Analyst Decision
- JKHY Hold
- UTHR Buy
- Analyst Count
- JKHY 9
- UTHR 12
- Target Price
- JKHY $176.22
- UTHR $495.08
- AVG Volume (30 Days)
- JKHY 1.0M
- UTHR 573.8K
- Earning Date
- JKHY 11-04-2025
- UTHR 10-29-2025
- Dividend Yield
- JKHY 1.40%
- UTHR N/A
- EPS Growth
- JKHY 20.28
- UTHR 16.08
- EPS
- JKHY 6.58
- UTHR 26.38
- Revenue
- JKHY $2,419,044,000.00
- UTHR $3,128,400,000.00
- Revenue This Year
- JKHY $6.98
- UTHR $13.68
- Revenue Next Year
- JKHY $6.45
- UTHR $5.63
- P/E Ratio
- JKHY $25.12
- UTHR $17.53
- Revenue Growth
- JKHY 7.75
- UTHR 13.50
- 52 Week Low
- JKHY $144.12
- UTHR $266.98
- 52 Week High
- JKHY $196.00
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- JKHY 60.66
- UTHR 67.47
- Support Level
- JKHY $159.78
- UTHR $444.04
- Resistance Level
- JKHY $168.43
- UTHR $464.27
- Average True Range (ATR)
- JKHY 3.71
- UTHR 15.68
- MACD
- JKHY 1.18
- UTHR 1.67
- Stochastic Oscillator
- JKHY 76.80
- UTHR 84.69
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.